PARP inhibitor for advanced breast cancer in PALB2 mutation carriers
Treatments studied
Part of Cancer, Genetic & congenital clinical trials.
This trial tests a drug that may help people with advanced breast cancer who have a specific genetic change (in the PALB2 gene). The drug is a PARP inhibitor, which works by targeting cancer cells that have trouble repairing their DNA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a change (mutation) in the PALB2 gene (and no mutations in BRCA1 or BRCA2)
- Your breast cancer has spread to other parts of the body (metastatic) and is either triple negative or hormone receptor positive/HER2 negative
- If you have triple negative cancer, you've had chemotherapy with anthracyclines and taxanes before
- If you have hormone receptor positive cancer, you've tried at least two previous treatments, including endocrine therapy and CDK4/6 inhibitors
- You are generally able to care for yourself (ECOG 0-2) and do not have severe organ problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This trial tests a combination of two drugs, capecitabine (a chemotherapy pill) and niraparib (a targeted therapy), for people with advanced breast cancer that has stopped responding to other treatments. The goal is to see if this combination can help control the cancer and improve outcomes.
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
This study tests a drug called olaparib (a PARP inhibitor) in people with triple-negative breast cancer that has returned or spread, and whose tumors do not have a BRCA gene mutation but do have a change called BRCA1 promoter methylation. The goal is to see if olaparib can help shrink or slow the cancer, based on this specific tumor feature.
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
Hear when a new Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.